Navigation Links
Sharp Edge Labs and SpectraGenetics Sign Agreement to Provide Better Assays for Studying G-Protein Coupled Receptors
Date:10/29/2013

PITTSBURGH, Oct. 29, 2013 /PRNewswire-iReach/ -- Sharp Edge Labs and SpectraGenetics, two Pittsburgh-based biotechnology companies, have entered into an Assay Development Agreement that will allow the companies to offer their industry leading assays for studying the detailed function of an important class of pharmaceutical targets, the G-Protein Coupled Receptors, or GPCRs.  GPCRs are the most common target of today's blockbuster drugs, including drugs for diseases ranging from hypertension and allergy to migraines, pain and cancer.  "While GPCRs are among the most-studied drug targets, we are just now learning important new aspects of how they work.  These assays provide unprecedented detail in understanding these new aspects of activity for the industry's most valuable drug targets" said Dr. Scott Sneddon, Ph.D., J.D., President and CEO of Sharp Edge Labs.  

(Photo: http://photos.prnewswire.com/prnh/20131029/MN04907)

"Working together, we can now offer a comprehensive set of tools for pharmaceutical and academic researchers including reagents and read-to-run assay kits, as well as assay services for profiling and screening compounds" added Dr. Reid Asbury, Ph.D., CEO of SpectraGenetics.  "Several large-pharma customers are already using the technology to study so-called 'ligand bias' or 'functional selectivity' of GPCRs.  By combining SpectraGenetics' catalog of over 150 GPCRs with Sharp Edge Labs' assay development expertise, we believe we can help researchers address any question in this important new field of drug research" he added.

SpectraGenetics provides research reagents to the pharma/biotech industry and academic labs.  SpectraGenetics has a large catalog of tagged genes, including a large selection of tagged GPCRs.   Sharp Edge Labs is the exclusive licensee of the Fluorogen Activating Peptide technology from CMU and provides assay products and services for pharma/biotech researchers in the areas of Receptors, Ion Channels and Transporters.  The company's web-sites are www.spectragenetics.com and www.sharpedgelabs.com.  Detailed images of the technology in use  suitable for print or web publication can be found at www.sharpedgelabs.com/media-images

Media Contact: Scott Sneddon, PhD, JD, Sharp Edge Labs, Inc., 412-475-9733, scott@sharpedgelabs.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Sharp Edge Labs, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rehrig Pacific Company Receives FDA Approval for New Reusable Sharps Container
2. Sharp Rees-Stealy Medical Centers Launches Asthmapolis Mobile Asthma Management Program
3. Safe in Commons "The Unfinished Agenda: Addressing the Challenges" Crystalizes Call for Unified Protection Against Needlestick and Sharps Injuries
4. Brain Resource Featured as Market Leader in SharpBrains New Report on The State of the Digital Brain Health Market 2012-2020
5. Daniels Sharpsmart Canada Awarded HealthPro Contract And Appoints Daniel Kennedy CEO Of Daniels Canada
6. Circassia Appoints Stewart Sharpe as Vice President Commercial Operations
7. Study Confirms Daniels Sharpsmart Helps Hospitals Reduce Carbon Footprint
8. Philips and Infraredx sign agreement for the resale of Infraredxs TVC Imaging System integrated with Philips interventional X-ray systems
9. Valeant Pharmaceuticals Announces Settlement Agreement With Anacor
10. InCube Labs Enters into an Agreement with the Engineering Research Center for Revolutionizing Metallic Biomaterials
11. Bioject Enters Into Agreement With Fondaco PTE LTD For Distribution Of Full Line Of Needle Free Injection Devices In Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
Breaking Medicine News(10 mins):